Novo Nordisk A/S expected to post earnings of DKK5.09 a share - Earnings Preview - TradingView

Novo Nordisk A/S NOVO_B is expected to show a rise in quarterly revenue when it reports results on November 5 for the period ending September 30 2025 The Bagsvaerd Denmark-based company is expected to report a 8.7% increase in revenue to DKK77.502 billion from DKK71.31 billion a year ago, according to the mean estimate from 9 analysts, based on LSEG data. (Majority Sales represents Total Revenue) ​LSEG's mean analyst estimate for Novo Nordisk A/S is for earnings of DKK5.09 per share. The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 17 "strong buy" or "buy," 8 "hold" and 2 "sell" or "strong sell." The mean earnings estimate of analysts had risen by about 1.0% in the last three months. ​ Wall Street's median 12-month price target for Novo Nordisk A/S is DKK435.00, about 27.4% above its last closing price of DKK315.95